Acta Scientific MEDICAL SCIENCES (ISSN: 2582-0931)

Volume 9 Issue 7 July 2025

Review Article

The Application of Organ-on-a-Chip Technology for Disease Modeling and Drug Testing

Sandeep Gundlapalli and Tawil Bill*

Department of Biotechnology and Bioinformatics, California State University Channel Islands (CSUCI), Camarillo, USA

***Corresponding Author:** Tawil Bill, Department of Biotechnology and Bioinformatics, California State University Channel Islands (CSUCI), Camarillo, USA.

DOI: 10.31080/ASMS.2025.09.2110

Received: May 12, 2025

Published: June 11, 2025

Abstract

Organ-on-chip (OoC) technology represents a significant advancement in the field of biomedical engineering, merging microfluidics with live cellular architectures to create dynamic models of human organ systems. This innovation extends beyond traditional methodologies by incorporating real-time analytics and advanced microfabrication techniques to simulate precise organ functionalities and inter-organ communications. Particularly, the integration of liver, heart, and kidney chips has enhanced drug metabolism studies, cardiotoxicity evaluations, and nephrotoxicity screenings, providing early detection capabilities that significantly reduce late-stage drug development failures.

The paper discusses novel multi-organ models that effectively replicate systemic human responses, offering insights into complex disease mechanisms and drug interactions. These include sophisticated models for diabetes management and infectious disease research, which utilize microfluidic systems to accurately mimic disease pathology and treatment responses. Additionally, the paper introduces regulatory developments and standardization challenges within the OoC field, emphasizing the role of the FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) program in fostering regulatory acceptance of OoC technologies.

The outlook of OoC technology is explored, highlighting the potential integration with artificial intelligence to enhance predictive modeling and therapeutic personalization. This technology promises to revolutionize drug development and personalized medicine by providing more accurate, efficient, and ethical research methodologies. Continued interdisciplinary collaboration and regulatory innovation are identified as crucial for realizing the full potential of OoC systems in advancing human health.

Keywords: Organ-on-Chip (OoC); Microfluidics; Biomedical Engineering; Drug Testing; Disease Modeling; Personalized Medicine; Multi-Organ Systems; Regulatory Standards; Artificial Intelligence (AI); Pharmacokinetics (PK)

Abbreviations

OoC: Organ-on-Chip; AI: Artificial Intelligence; iPSCs: Induced Pluripotent Stem Cells; PDMS: Polydimethylsiloxane; FDA: Food and Drug Administration; EMA: European Medicines Agency; ISTAND: Innovative Science and Technology Approaches for New Drugs; BBB: Blood-Brain Barrier; DM: Diabetes Mellitus; T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; PK: Pharmacokinetics; ADME: Absorption; Distribution; Metabolism; and Excretion; PD: Pharmacodynamics

Introduction

Organ-on-chip technology, emerging at the intersection of bioengineering and microfluidics, is revolutionizing medical research and pharmaceutical development by offering microscale

simulations of human organ systems [1]. These systems mimic human organ physiology more accurately than traditional 2D cultures, providing a dynamic platform to observe cellular behaviors and interactions in real time [1]. For example, recent studies have shown that liver-on-chip models can replicate the drug metabolism rates observed in vivo with over 90% accuracy, offering a promising tool for pharmacokinetic studies [2].

Technology was primarily developed in response to the need for more predictive and ethically responsible research models in drug screening and disease modeling [3]. It integrates live human cells within microfabricated environments that recreate the mechanical and biochemical stimuli of the human body, thereby capturing the complex interactions of living tissues [3]. This innovation not only reduces reliance on animal testing—which often fails to predict human-specific responses—but also significantly shortens the drug development cycle [4].

Heart-on-a-chip and lung-on-a-chip models are particularly notable applications, allowing for the observation of cardiac and respiratory responses to drugs under precisely controlled conditions [5]. These models have been instrumental in identifying cardiotoxicity in early drug development stages, reducing the likelihood of late-stage pharmaceutical failures [6].

Moreover, the integration of real-time imaging and analytics with organ-on-chip systems facilitates detailed studies of disease progression and treatment efficacy, providing insights that were previously unattainable in static culture systems or animal models [7]. For instance, cancer-on-a-chip models have revealed novel pathways of tumor metastasis and resistance to chemotherapy, thereby informing more targeted cancer treatment strategies [7].

Despite their significant advantages, the adoption of organ-on-chip technologies in mainstream research and clinical practice is hindered by high costs and operational complexities [8]. Moreover, a 2023 study highlighted the lack of standardization in chip design and operation as a major barrier to reproducibility and broader acceptance [9].

The future of organ-on-chip technology appears promising, with ongoing advancements in microfabrication and the development of multi-organ systems that simulate entire physiological responses to substances [10]. These systems could potentially transform drug testing by providing more comprehensive insights into the systemic impacts of drugs and diseases [10].

As organ-on-chip technology integrates with cutting-edge fields like artificial intelligence, its potential to tailor medical treatments to individual physiological profiles becomes increasingly feasible, marking a significant step towards personalized medicine [11]. For example, a recent breakthrough using AI to analyze organ-on-chip data has improved the predictive accuracy of drug responses by up to 40%, significantly impacting how treatments are developed and administered [11].

Market value and commercialization

The rgan-on-chip market is on an upward trajectory, expected to grow from an estimated USD 123 million in 2024 to USD 631 million by 2029, demonstrating a remarkable CAGR of 38.6% [12] (Figure – 1). This growth is primarily driven by the critical demand for more reliable and ethically sound alternatives to traditional animal testing in drug development and disease modeling [13].



Figure 1: Organ-On-Chip Market Size and Global Industry Forecast 2029. MarketsandMarkets, www.marketsandmarkets.com/Market-Reports/organs-on-chips-market-144117291.html.

In terms of regional analysis, North America holds the largest market share, propelled by robust investments in biotechnology and favorable regulatory frameworks [13] (Figure – 2). The

European market is also expanding significantly, supported by stringent regulations on animal testing and increasing funding for biomedical research [14].

Figure 2: Organ-On-Chip Market Size & Growth Statistics by 2030. Allied Market Research,www.alliedmarketresearch.com/organ-on-chip-market.

Significant contributions from industry leaders such as Emulate and Organovo, who are pioneering the development of liver and heart chips, respectively, underscore the technology's potential to transform drug efficacy and toxicity assessments [15]. Moreover, these companies are engaging in strategic collaborations with pharmaceutical giants to integrate organ-on-chip technology into existing R&D pipelines, thereby enhancing its commercial footprint [6].

Investment and funding trends

Investment in the organ-on-chip sector is robust, with venture capital funding exceeding $100 million in 2024 alone. This funding is critical for advancing technological innovations and scaling up production capabilities to meet growing industry demands [16].

Regulatory landscape

Regulatory bodies, notably the FDA, have begun recognizing the potential of organ-on-chip systems to significantly enhance drug testing protocols [17]. Recent guidelines have advocated for their integration into safety assessment protocols, which is anticipated to further drive market adoption and development [17].

The global shift towards personalized medicine and the need for faster, more accurate testing methods are bolstering the adoption of organ-on-chip technologies [18]. As technology matures, it is expected to catalyze significant advancements in drug discovery and development, thereby reshaping the landscape of pharmaceutical research and biotechnology [18].

Principles and design of organ-on-chip systems

Organ-on-chip (OoC) systems represent a pivotal advancement in biomedical engineering, combining microengineering techniques with cellular biology to emulate the functionalities of human organ systems [19]. These devices are meticulously engineered to replicate the physiological responses of organs under various pharmacological and physiological stimuli, offering revolutionary platforms for drug testing, disease modeling, and the development of personalized medicine solutions [15].

Design principles

OoC systems are intricately designed to simulate the microenvironment of human tissues, specifically focusing on the accurate emulation of mechanical and biochemical cues [19]. Typical OoC designs include precisely fabricated microfluidic channels that are about 50 to 600 microns in width [15]. These channels not only mimic vascular structures for the effective delivery and removal of substances, thereby ensuring nutrient delivery and waste removal critical for cell survival and function, but also support complex, organ-specific cellular architectures [15]. For Example, endothelial cells are used in vascular models and hepatocytes in liver models, which are positioned to facilitate organ-specific functions and interactions (Figure – 3). This level of design enhances the system's ability to mimic dynamic organ responses, improving the reliability and applicability of biological assays in clinical research [1].

Microfabrication techniques

The construction of OoCs is grounded in advanced microfabrication techniques, including soft lithography,



Figure 3: Vargas, Ronny., et al. "Organ-On-a-Chip Systems for New Drugs Development. ADMET and DMPK, vol. 9, no. 2, 20 Mar. 2021, pp. 111–141, https://doi.org/10.5599/admet.942.

Examples of OoC devices. A) Three-layer chip with a cell culture receptacle on the bottom plate, and multiple channel connectors for feed and signal control on the top plate. Adapted from [46] with permission from The Royal Society of Chemistry. Copyright (2018) B) A Two-channel OoC for the simulation of an epithelial tissue. Reproduced from [47] under terms of the Creative Commons Attribution License. C) OoC model for the simulation of the blood-brain barrier with gel suspended astrocytes and neurons.

photolithography, and 3D printing, which are utilized to construct channels with widths as precise as 10 microns [20]. These techniques allow for the development of detailed microstructures that provide mechanical support and guide cellular alignment, crucial for the maintenance of physiological architecture of the organs being simulated [8]. This microengineering capability facilitates the creation of complex, multi-layered organ models on a single chip, which are instrumental in studying both inter-organ communication and systemic responses to external stimuli [19].

Integration of multiple organ models

Contemporary OoC platforms often feature an integration of multiple organ models into a single system, designed to simulate whole-body physiological responses to drugs or pathological conditions [1]. This complex integration requires precise fluidic management through microchannels that interconnect different organ models, ensuring that each model maintains its unique physiological environment yet allowing for inter-organ signaling and metabolic exchanges [20]. Such integrative designs are critical for examining the holistic effects of medical treatments and understanding multifaceted disease mechanisms, providing valuable insights into systemic pharmacological impacts [15].

Material selection and challenges

The selection of materials in OoC systems is a critical factor in their success, as the materials must accurately mimic the native mechanical and biochemical properties of the tissue environment [19]. PDMS is widely used because of its optical clarity, low auto fluorescence, and gas permeability, but it also poses challenges due to the absorption of hydrophobic molecules [8]. In response, the field is moving towards the use of advanced hydrogels that provide better mimicry of the extracellular matrix, offering enhanced cell functionality and system longevity (Figure – 4). These hydrogels are engineered to match the stiffness and porosity of biological tissues, which are typically in the range of 0.1 to 50 kPa depending on the tissue type, thereby enhancing the physiological relevance of the chips [20].



Figure 4: Yin, Hongze., et al. "Advances in the Model Structure of in Vitro Vascularized Organ-On-a-Chip". Cyborg and Bionic Systems, vol. 5, 1 Jan. 2024, https://doi.org/10.34133/cbsystems.0107.

Applications in disease modeling

Organ-on-chip platforms have become essential tools for accurately modeling human diseases, allowing for detailed examination of pathological processes at a cellular and molecular level [19]. These systems create physiologically relevant microenvironments that closely simulate specific organ characteristics, making them especially valuable in studying complex diseases like cancer, cardiovascular disorders, neurological conditions, and infectious diseases [19].

Cancer modeling

Tumor-on-chip models offer sophisticated environments for studying tumor biology, capturing key aspects such as tumor heterogeneity, drug penetration, and metastatic behavior [15]. For instance, Flont introduced a layered cancer-on-a-chip model that mimics the multilayered structure of solid tumors, effectively representing gradients in drug penetration and cellular resistance typically observed clinically [21]. This approach allowed real-time monitoring of anticancer drug diffusion, cytotoxic effects, and the evolution of resistance mechanisms [21] (Figure – 5).



Figure 5: Flont, Magdalena., et al. "A Layered Cancer-On-a-Chip System for Anticancer Drug Screening and Disease Modeling". The Analyst, vol. 148, no. 21, 2023, pp. 5486–5495, https://doi.org/10.1039/d3an00959a.

Additionally, Herreros developed a melanoma-on-a-chip model incorporating microneedle-based drug delivery methods to simulate realistic therapeutic administration, enhancing the predictability of melanoma treatments [22]. This system provided valuable pharmacokinetic data on drug distribution within melanoma tissues, illustrating the effectiveness of novel therapeutic strategies [22].

Cardiovascular disease modeling

Heart-on-chip technologies are advancing the study of cardiovascular diseases by replicating both mechanical and biochemical properties of cardiac tissues [3]. Wang successfully utilized patient-derived induced pluripotent stem cells (iPSCs) to model Barth syndrome, demonstrating disease-specific metabolic dysfunction and impaired contractility within heart-on-chip platforms [3]. This model provided critical insights into mitochondrial cardiomyopathy and was utilized to screen potential therapeutic interventions targeted at mitochondrial function restoration [3].

Moreover, Rexius-Hall., *et al*. created a myocardial infarct border-zone-on-a-chip featuring precise oxygen gradients, mimicking ischemic and non-ischemic cardiac regions post-heart attack [5]. This platform revealed distinct cellular responses and differential gene expression profiles, significantly aiding the targeted development of therapies aimed at ischemic heart tissue recovery [5] (Figure – 6).



Figure 6: Rexius-Hall, M. L., Khalil, N. N., Escopete, S. S., Li, X., Hu, J., Yuan, H., Parker, S. J., & McCain, M. L. (2022). A myocardial infarct border-zone-on-a-chip demonstrates distinct regulation of cardiac tissue function by an oxygen gradient. Science Advances, 8(49). https://doi.org/10.1126/sciadv.abn7097

Neurological disease modeling

Neurological diseases like ALS and Alzheimer's disease have benefited significantly from organ-on-chip innovations, enabling more accurate simulation of neural tissue physiology and the blood-brain barrier [9]. Santoso and McCain developed a neuromuscular disease-on-a-chip, successfully modeling ALS pathology by integrating motor neurons and muscle tissues and demonstrating impaired neuromuscular signaling like clinical presentations of ALS [9].

This platform facilitated testing of neuroprotective compounds, providing meaningful data on drug efficacy and therapeutic potential [9].

Choi., *et al.* introduced a blood-brain barrier (BBB)-on-a-chip for exploring nano shuttle-mediated drug delivery across tight junctions, critical for CNS-targeted therapeutics [23]. This model accurately replicated selective permeability, significantly improving preclinical evaluation of drug candidates intended for treating neurological diseases [23] (Figure – 7).



Figure 7: Choi, Jeong-Won., et al. "Organ-On-a-Chip Approach for Accelerating Blood–Brain Barrier Nano shuttle Discovery". ACS Nano, vol. 18, no. 22, 22 May 2024, pp. 14388–14402, https://doi.org/10.1021/acsnano.4c00994.

Infectious disease modeling

The onset of the COVID-19 pandemic accelerated the application of organ-on-chip platforms in infectious disease research, particularly for modeling viral pathogenesis and host immune responses [24]. Crespilho developed a "pandemics-on-a-chip" concept combining respiratory and vascular cell types to investigate SARS-CoV-2 infection mechanisms and immune cell interactions under safe and controllable microenvironments [24]. These models offered valuable insights into viral replication dynamics and were instrumental in screening antiviral drugs and immune modulators, significantly reducing reliance on traditional animal models [24].

Similarly, Tanvir emphasized lung-on-a-chip and gut-on-a-chip systems for investigating respiratory and gastrointestinal viral infections, illustrating how these models accurately replicate host-pathogen interactions and immune cell recruitment in real-time [19]. Such organ-specific chips have rapidly become essential tools for high-throughput antiviral drug screening and vaccine testing, providing results more predictive of human responses compared to animal studies [19].

Diabetes mellitus (DM) modeling

Diabetes Mellitus (DM) represents a global health concern characterized by chronic disorders involving dysregulated glucose metabolism. Type 1 diabetes (T1DM) involves autoimmune destruction of pancreatic β-cells, whereas type 2 diabetes (T2DM) results from β-cell dysfunction and insulin resistance [25]. Traditional in vivo models for diabetes research often fail to accurately reflect human disease mechanisms due to fundamental physiological differences, highlighting the urgent need for advanced human in vitro models [25].

Organ-on-a-chip (OoC) technology has revolutionized diabetes research by integrating stem cell-derived human β-cells within microfluidic systems, thereby accurately replicating human physiological conditions and disease pathogenesis. Such systems facilitate precise monitoring of insulin secretion dynamics and β-cell interactions with immune cells, critical for understanding autoimmune mechanisms in T1DM [25]. These chips also allow investigation into β-cell dysfunction under metabolic stressors characteristic of T2DM, providing platforms for targeted drug screening and therapeutic discovery [25].

A prominent example involves the integration of pancreatic islets-on-chip with liver and muscle tissues to model systemic

glucose metabolism and insulin signaling, thereby enhancing our understanding of inter-organ interactions involved in diabetes pathology [25]. Advanced multi-organ chips can simulate the metabolic complications of diabetes, such as diabetic nephropathy and retinopathy, expanding the scope of OoC applications to comprehensive disease modeling and precision medicine [25] (Figure – 8).



Figure 8: Rogal, Julia., et al. "Stem-Cell Based Organ-On-a-Chip Models for Diabetes Research". Advanced Drug Delivery Reviews, vol. 140, Feb. 2019, pp. 101–128, https://doi.org/10.1016/j.addr.2018.10.010.

Kidney disease modeling

Kidney-on-a-chip technologies have significantly enhanced nephrology research by accurately emulating renal physiology and disease processes. These systems employ microfluidic technology to cultivate renal cell types, including glomerular endothelial cells, podocytes, and proximal tubule epithelial cells (PTECs), in structured perfusable channels, accurately replicating kidney functionality under physiological and pathophysiological conditions [26].

Specific kidney-on-a-chip models such as glomerulus-on-a-chip replicate the filtration barrier and demonstrate utility in modeling diabetic nephropathy and hypertensive nephropathy, offering critical insights into disease mechanisms and therapeutic targets [26]. Proximal tubule-on-a-chip systems effectively simulate renal reabsorption and secretion processes, allowing in-depth analysis of drug nephrotoxicity for compounds like cisplatin and cyclosporine A, significantly improving nephrotoxicity screening accuracy [26].

Nephron-on-a-chip, which integrates multiple renal cells types, represents a significant advancement, mimicking entire nephron functionality. These models have shown great promise for investigating drug-induced kidney injuries and studying complex renal metabolic and endocrine functions [26]. Moreover, integrated liver-kidney-on-a-chip models provide a platform for examining the combined impact of hepatic metabolism and renal excretion on drug toxicity, greatly enhancing preclinical safety evaluations [26].

Advancements in drug testing and development

Organ-on-a-chip (OoC) technology represents a transformative innovation for drug discovery, offering improved physiological relevance and higher predictive accuracy compared to traditional vitro and animal models [15]. The complexity of human physiology often results in drugs that pass animal testing but fail in clinical trials, underscoring the urgent need for better preclinical platforms [19]. OoC systems effectively simulate human tissue responses, significantly reducing the translational gap from preclinical results to human clinical outcomes [6].

OoC systems greatly enhance the understanding of pharmacokinetics (PK) including absorption, distribution, metabolism, and excretion (ADME) and pharmacodynamics (PD), which describe the biological effects and mechanisms of drugs [15]. Vargas., *et al*. highlighted how OoC technologies provide advanced models for hepatic metabolism studies, allowing real-time monitoring of drug metabolism, toxicity, and the interactions among liver-specific cell types. These liver-on-a-chip systems facilitate early detection of hepatotoxicity, drastically reducing drug attrition rates during later stages of clinical trials [15].

Similarly, kidney-on-chip platforms have significantly improved the prediction of nephrotoxic effects, a common cause of drug withdrawal and clinical trial failure (Huang, 2024). By simulating human proximal tubules, these models accurately replicate renal reabsorption and filtration processes, enabling researchers to identify nephrotoxic potential at an earlier phase in drug development [26]. Integration of renal and hepatic modules into

multi-organ-chip platforms has further refined systemic drug evaluations, captured inter-organ communication and provided comprehensive toxicity profiles [26].

Neuromuscular disorders have also seen benefits from OoC innovations. Santoso and McCain demonstrated neuromuscular models integrating human-derived motor neurons and muscle cells to study ALS, providing essential data on drug-induced neuroprotection and synaptic integrity. This approach offers significant promise in neuropharmacology, streamlining drug testing protocols for disorders previously challenging to study in traditional setups [9].

Cancer pharmacology has greatly advanced through the adoption of OoC models, particularly in studying tumor microenvironments and drug resistance mechanisms [22]. Herreros., *et al*. introduced melanoma-on-chip systems which enhanced drug testing accuracy by simulating realistic tumor conditions, including nutrient gradients and mechanical stresses, facilitating precise evaluation of drug distribution and therapeutic efficacy. Likewise, Flont., *et al*. developed layered cancer-on-chip systems to model drug penetration and cellular response realistically, significantly improving predictive accuracy for clinical anticancer drug efficacy [21].

Cardiac OoC models have revolutionized drug cardiotoxicity assessments. Rexius Hall developed myocardial infarct border-zone-on-chip models, capturing ischemic gradients and cellular responses to cardioprotective drugs [5]. These cardiac models provide insights into arrhythmogenic potential and cardiotoxic effects early in the drug screening process, substantially mitigating risks associated with drug-induced cardiac side effects [5]. Additionally, Wang., *et al*. modeled Barth syndrome using heart-on-chip systems derived from patient-specific induced pluripotent stem cells (iPSCs), successfully predicting therapeutic responses and metabolic outcomes [3].

Diabetes and metabolic disorder research have notably benefited from multi-organ-chip systems integrating pancreatic, hepatic, and muscle tissues to model insulin signaling and glucose homeostasis accurately [25]. These models facilitate drug efficacy screening for diabetes management, enabling precise quantification of insulin secretion and metabolic regulation in response to novel therapeutic agents [25].

The incorporation of advanced sensing technologies within OoC platforms further improves real-time monitoring capabilities. She., *et al*. integrated hydrogel-based strain sensors into dynamic OoC models, providing continuous monitoring of tissue stress responses to pharmacological agents [11]. This technology significantly enhances the resolution and precision of pharmacodynamic studies, providing real-time insights into drug efficacy and tissue-level impacts [11].

Advancements in regulatory acceptance, including initiatives by the FDA and European Medicines Agency, highlight increasing recognition of OoC technologies as viable alternatives to traditional testing paradigms [6].

The FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program, for instance, recently accepted organ-on-a-chip submissions, indicating a pivotal shift toward regulatory endorsement and validation of OoC technology for drug safety and efficacy evaluation [17]. Regulatory bodies increasingly view OoC technologies as promising alternatives to traditional methods, due to their ability to capture critical aspects of human biology and predict patient responses more accurately [20].

The predictive capability of OoC models in drug-induced toxicity has been clearly demonstrated in hepatic applications. Rubiano., *et al*. (2021) showcased a reproducible liver micro physiological system capable of assessing drug-induced liver injury (DILI), metabolic clearance, and bioaccumulation of pharmaceuticals, thereby significantly improving safety evaluations in early drug development [2]. This system successfully predicted hepatotoxic effects of multiple known liver toxins with high precision, emphasizing its potential utility in regulatory toxicology [2].

Similarly, OoC systems have shown great utility in screening environmental toxicants and chemicals. Akarapipad., *et al*. used liver and kidney chips to evaluate chemical toxicity, highlighting superior accuracy and sensitivity compared to conventional cell assays [27]. Their findings demonstrated the capability of OoC technology in predicting adverse reactions at lower exposure levels, significantly enhancing the toxicological risk assessment process for environmental safety regulations [27].

In the context of ophthalmology, Kravchenko., *et al*. demonstrated significant advances using ocular OoC models, which successfully

simulated corneal and retinal tissues [28]. These ocular chips allow detailed drug permeability studies and accurate assessment of drug-induced ocular toxicity, greatly reducing reliance on animal models traditionally employed in ophthalmic drug development [28].

Organ-on-chip platforms have also advanced drug testing protocols through precision and repeatability in neuromuscular disease research. Bettadapur., *et al*. demonstrated prolonged culture of aligned skeletal myotubes on gelatin hydrogel-based muscle chips, providing robust systems to evaluate muscular responses to pharmaceuticals and biomolecular agents [29]. These models not only improve the accuracy of drug screening but also facilitate detailed studies of drug-induced muscle regeneration and degeneration pathways [29].

Significant developments have also occurred in skin-on-a-chip models. Barros., *et al*. (2024) engineered a human skin -on-a-chip platform specifically designed for evaluating microneedle-driven drug delivery systems [30]. This model significantly enhanced preclinical testing accuracy for skin treatments and topical drug formulations, providing realistic simulations of dermal absorption and localized drug effects [30].

Integration of real-time analytical technologies within OoC systems is further advancing drug development capabilities. For example, Tsagkaris., *et al*. (2019) developed a hybrid lab-on-a-chip injector system, capable of autonomous chemical screening, significantly enhancing high-throughput drug testing efficiency [31]. Such integration of automated systems within OoC technology accelerates drug discovery timelines, reducing resource consumption and facilitating broader application in pharmaceutical testing environments [31].

The versatility of OoC platforms has also facilitated their integration with advanced artificial intelligence (AI) and machine learning techniques. Meneses., *et al*. discussed the integration of AI-driven data analytics with OoC platforms, significantly improving predictive modeling of drug responses [32]. This combination enables rapid, large-scale pharmacological screening and efficient optimization of drug candidates before clinical trials, effectively reducing attrition rates and development costs [32].

overall, these technological advancements position organ-on-chip systems as essential tools for future drug development pipelines. Their increased adoption by pharmaceutical companies and acceptance by regulatory authorities promises a paradigm shift in drug testing, substantially enhancing efficiency, precision, and clinical translatability of preclinical studies [19].

Standardization and regulatory considerations

The rapid development and implementation of Organ-on-chip (OoC) technologies necessitate robust standardization frameworks and clear regulatory pathways to ensure broad acceptance within pharmaceutical and biomedical sectors [32]. Despite the potential of OoC systems to revolutionize preclinical testing, inconsistent manufacturing protocols, variability in cell sourcing, and the absence of universally accepted validation guidelines present significant barriers [33]. Consequently, standardization has emerged as an essential requirement to guarantee reproducibility, reliability, and regulatory acceptance across various OoC platforms [2].

Manufacturing and material standardization

Material variability, particularly regarding the use of Polydimethylsiloxane (PDMS), significantly impacts reproducibility, as PDMS often exhibits high adsorption rates of hydrophobic molecules, potentially altering drug efficacy and toxicity results [20]. Scott Campbell emphasized the necessity for alternative materials, such as thermoplastic polymers, hydrogels, and biocompatible elastomers, to standardize manufacturing processes and minimize variability [20]. Moreover, standardizing bioprinting methods is equally critical, as differences in bioprinter settings and biomaterial formulations directly influence the biological fidelity and reproducibility of printed OoC systems [4].

Biological standardization and validation

The establishment of biologically relevant and reproducible assays is another critical standardization challenge. Rubiano., *et al*. illustrated the importance of developing standardized assays for liver chips, highlighting the need for consistent methodologies to assess drug-induced hepatotoxicity, metabolism, and bioaccumulation [2]. Similarly, precise biomarker definitions and standardized functional assays for kidney-on-a-chip platforms were underscored by Huang., *et al*. to ensure reproducible nephrotoxicity evaluations across laboratories [26].

Santoso and McCain also stressed the need for standardized assays for neuromuscular models, facilitating consistent drug screening protocols across research groups [9]. Similarly, Choi., *et al*. emphasized establishing reliable and reproducible permeability measurements in blood-brain barrier (BBB)-on-chip systems, essential for drug delivery validation and regulatory approval [23].

Regulatory challenges and milestones

Regulatory acceptance remains a major hurdle for the broader adoption of OoC technologies. Regulatory bodies, particularly the FDA and EMA, have recognized the potential of OoC systems, yet formalized guidelines and qualification procedures are still developing [17]. The FDA's ISTAND initiative recently validated an OoC submission, marking a critical regulatory milestone that demonstrates the increasing integration of OoC technologies into standard drug testing frameworks [17].

Moreover, Sonia Gomes Teixeira (2023), through the French National Agency for Medicines and Health Products Safety (ANSM), highlighted new regulatory challenges for OoC technologies, proposing essential criteria such as functional validation, robustness, and clinical predictive accuracy [34]. Such initiatives suggest regulatory readiness to embrace OoC, contingent upon comprehensive standardization efforts [34].

Standardization in toxicology and environmental testing

Standardization efforts extend to toxicological and environmental safety assessments. Akarapipad., *et al*. illustrated how OoC platforms for environmental toxicology assays must adhere to stringent validation protocols, significantly enhancing their credibility for regulatory risk assessment processes [27]. Similarly, Nitsche., *et al*. emphasized the standardization of chemical risk assessment procedures using OoC technologies, facilitating their integration into next-generation toxicology frameworks and regulatory paradigms [8].

Device integration and analytical standardization

Standardization also encompasses the integration of advanced sensing technologies into OoC platforms. She., *et al*. introduced hydrogel-based strain sensors requiring clearly defined validation protocols to assure consistent tissue response monitoring across laboratories [11]. Additionally, Tsagkaris., *et al*. underscored the importance of standardizing automated screening systems to improve reproducibility and reliability in drug and chemical testing [31].

Cellular sources and culture conditions

Standardization of cellular sources, including primary cells, iPSC-derived cells, and established cell lines, is critical. Rogal., *et al*. argued that consistent cell sourcing, handling, and maintenance protocols are essential for reproducibility in diabetes research platforms, significantly enhancing the regulatory acceptability of metabolic assays [25].

Similarly, Bettadapur., *et al*. (2016) emphasized standardized culture protocols for skeletal muscle tissue, critical for reproducibly evaluating drug responses [29]. Standardized maintenance protocols for cell culture, differentiation conditions, and biomaterial interactions ensure consistent outcomes across diverse laboratories and regulatory submissions [29].

Multi-organ standardization and regulatory integration

The standardization of multi-organ-chip models presents additional complexity, requiring harmonization of inter-organ interactions and systemic response benchmarks. Jong Hwan Sung (2022) highlighted the need for standardized body-on-a-chip models, including well-defined physiological parameters and performance criteria to facilitate regulatory integration and pharmaceutical adoption [6].

Meneses., *et al*. (2024) suggested integrating standardized artificial intelligence (AI)-driven analytics to enhance reproducibility and predictive accuracy across multi-organ platforms, significantly streamlining regulatory qualification processes [32].

Challenges and limitations

Despite promising advancements, Organ-on-Chip (OoC) technology faces several critical challenges that currently limit its widespread adoption. One significant hurdle involves accurately recapitulating complex organ-level physiological processes, particularly the intricate dynamics of disease states [35]. For example, myocardial OoC models have faced challenges in reproducing maladaptive cardiac remodeling at multiscale levels, highlighting limitations in current design approaches for chronic conditions [35].

Additionally, maintaining long-term cellular viability and functional fidelity within OoC devices remains challenging, particularly in models of post-infarct myocardial tissues [36]. Khalil and McCain emphasized that engineering realistic cellular microenvironments, including proper oxygen gradients and extracellular matrix interactions, poses technical difficulties affecting consistency and reproducibility of outcomes [36].

Another limitation is the scalability and integration complexity of multi-organ systems. Current approaches often struggle to effectively model inter-organ communication and systemic drug responses due to the technological complexity and associated cost constraints [40]. Integration of advanced sensors, computational analytics, and robust microfluidic systems demands significant resources and interdisciplinary expertise, which are not uniformly available across laboratories and industries [40].

Furthermore, standardized protocols and clear regulatory pathways are still evolving, contributing to uncertainty around commercialization and broader regulatory acceptance [41]. Alver., *et al*. (2024) have clearly identified these regulatory roadblocks as critical factors limiting the widespread dissemination and deployment of OoC technologies within industry and healthcare applications [41].

Biological complexity and variability, particularly when employing primary cells or patient-derived cells like induced pluripotent stem cells (iPSCs), add another layer of unpredictability, potentially compromising the reliability and reproducibility of OoC models [39]. For instance, organoid-based OoC systems, despite their higher biological relevance, face considerable challenges due to cellular heterogeneity and inconsistent differentiation patterns, complicating standardized assay development and drug screening applications [39].

Addressing these limitations requires significant innovation in biomaterials, microfabrication techniques, standardization practices, and regulatory harmonization, thus highlighting the necessity for sustained interdisciplinary efforts [37].

Future perspectives and emerging trends

Looking ahead, OoC technologies are poised to significantly evolve, driven by emerging interdisciplinary trends and technological breakthroughs. One prominent trend is the integration of OoC with advanced bio fabrication methods, such as bioprinting, to facilitate the creation of highly organized, complex tissue architectures that better mimic native organ structures [37]. Bio printed chips promise substantial improvements in biological fidelity, scalability, and reproducibility, potentially revolutionizing drug testing and precision medicine strategies [37].

Integration with artificial intelligence (AI) and advanced computational modeling will also significantly enhance the analytical power and predictive accuracy of OoC technologies. Real-time data collection combined with AI-driven analytics will enable sophisticated analysis of drug responses, accelerating therapeutic discoveries and personalized medicine approaches [38].

Furthermore, there is growing interest in developing multi-organ or body-on-a-chip models capable of simulating comprehensive systemic human responses. Ashammakhi., *et al*. highlighted the critical need to develop fully integrated multi-organ systems, potentially including immune and endocrine interactions, which could drastically improve predictions of systemic drug efficacy and toxicity [40].

Emerging research also focuses on using OoC platforms for modeling complex physiological phenomena beyond standard organ functionalities, such as hormonal signaling and stress responses [38]. Maxey., *et al*. for example, demonstrated sophisticated myometrial models that regulate oxytocin-induced calcium transients and gene expression, showcasing future possibilities in reproductive health research and hormonal therapeutics [38].

To facilitate these advanced applications, significant regulatory and standardization advancements are expected. Regulatory bodies are becoming more actively involved, potentially accelerating the formal recognition and qualification of OoC technologies through clearer guidelines and harmonized international standards [41].

Conclusion

The trajectory of organ-on-chip (OoC) technology underscores its transformative impact on modern biomedical research and pharmaceutical development. As a convergence of microengineering, cellular biology, and microfluidics, OoC platforms offer unprecedented simulations of human organ functions, significantly refining drug efficacy assessments and

disease investigations. This sophisticated technology mimics human physiological responses at the microscale, enhancing the predictive accuracy of preclinical trials and reducing reliance on traditional animal models which often fail to replicate human-specific outcomes.

The capabilities of OoC systems to replicate organ-specific functionalities—such as the intricate dynamics of liver metabolism or cardiac responses to pharmacological agents—have proven instrumental in identifying potential drug toxicities early in the development process. For instance, liver-on-chip models effectively mirror human drug metabolism, providing critical insights that prevent the advancement of potentially toxic substances.

Despite the promise shown by OoC technologies, their integration into mainstream research and clinical settings is hampered by challenges such as high costs, technical complexities, and the lack of standardized protocols which affect reproducibility and scalability. These challenges underscore the need for robust frameworks for standardization and regulatory acceptance that can adapt to the pace of technological advancements.

The future of OoC technology is vibrant with potential, particularly with the integration of advanced computational tools like artificial intelligence (AI). This synergy is poised to unlock sophisticated analyses of complex datasets, leading to more nuanced understandings of diseases and more personalized therapeutic interventions. As OoC technology continues to evolve, it is expected to play a pivotal role in the shift towards personalized medicine, offering more tailored and effective treatment options based on individual physiological responses.

Ultimately, the success of OoC platforms will depend on collaborative efforts among researchers, engineers, and regulatory bodies to refine the technology and establish comprehensive guidelines that ensure safety, reliability, and clinical relevance. Such advancements will pave the way for a new era in drug development and medical research, characterized by greater efficiency, precision, and customization in healthcare solutions.

Funding Sources

There is no funding to report on this study.

Conflict of Interest

Authors declare that there is no conflict of interest.

Acknowledgements

Sandeep Gundlapalli expresses appreciation to Professor Bill Tawil for his guidance on the framework of this review and for his insightful lectures on organ on a chip, which greatly contributed to my research.

Bibliography

1. Li Z., *et al*. "Microfluidic Organ-on-a-Chip System for Disease Modeling and Drug Development". *Biosensors* 12.6 (2022): 370.

2. Rubiano A., *et al*. "Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation". *Clinical and Translational Science* 14.3 (2021): 1049-1061.

3. Wang G., *et al*. "Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies". *Nature Medicine* 20.6 (2014): 616-623.

4. Thakare K., *et al*. "Bioprinting of Organ-on-Chip Systems: A Literature Review from a Manufacturing Perspective". *Journal of Manufacturing and Materials Processing* 5.3 (2021): 91.

5. Rexius-Hall M L., *et al*. "A myocardial infarct border-zone-on-a-chip demonstrates distinct regulation of cardiac tissue function by an oxygen gradient". *Science Advances* 8.49 (2022).

6. HWAN SUNG J. "From organ-on-a-chip towards body-on-a-chip". *BIOCELL* 46.5 (2020): 1177-1180.

7. Stavrou M., *et al*. "Organ-on-chip systems as a model for nanomedicine". *Nanoscale* 15.23 (2023): 9927-9940.

8. Nitsche K S., *et al*. "Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review". *Archives of Toxicology* 96.3 (2022): 711-741.

9. Santoso JW and McCain ML. "Neuromuscular disease modeling on a chip". *Disease Models and Mechanisms* 13.7 (2020).

10. Singh D., *et al*. "Journey of organ on a chip technology and its role in future healthcare scenario". *Applied Surface Science Advances* 9 (2022): 100246.

11. She W., *et al*. "Hydrogel Strain Sensors for Integrating into Dynamic Organ-on-a-Chip". *Small* 21.7 (2025).

12. Organ-On-Chip Market Size and Global Industry Forecast 2029. MarketsandMarkets.

13. Organ-On-Chip Market Size and Growth Statistics by 2030. Allied Market Research.

14. Organ-On-Chip Market Size and Share Analysis - Industry Research Report - Growth Trends.

15. Vargas Ronny., *et al*. "Organ-On-a-Chip Systems for New Drugs Development. ADMET and DMPK 9.2 (2021): 111-141.

16. Organ on a Chip Market Size, Share and Trends Report 2030.

17. FDA Center. "FDA Accepts First ISTAND Proposal". U.S. Food and Drug Administration, (2024).

18. Ma Chao., *et al*. "Organ-On-a-Chip: A New Paradigm for Drug Development". *Trends in Pharmacological Sciences* 42.2 (2021): 119-133.

19. Ahmed Tanvir. "Organ-On-a-Chip Microengineering for Bio-Mimicking Disease Models and Revolutionizing Drug Discovery". *Biosensors and Bioelectronics: X* 11 (2022): 100194.

20. Campbell Scott B., *et al*. "Beyond Polydimethylsiloxane: Alternative Materials for Fabrication of Organ-On-a-Chip Devices and Microphysiological Systems". *ACS Biomaterials Science and Engineering* 7.7 (2020): 2880-2899.

21. Flont Magdalena., *et al*. "A Layered Cancer-On-a-Chip System for Anticancer Drug Screening and Disease Modeling". *The Analyst* 148.21 (2023): 5486-5495.

22. Herreros Pedro., *et al*. "Melanoma-On-a-Chip Model for Anticancer Drug Injecting Delivery Method". *SLAS Technology* 29.6 (2024): 100219.

23. Choi Jeong-Won., *et al*. "Organ-On-a-Chip Approach for Accelerating Blood-Brain Barrier Nano shuttle Discovery". *ACS Nano* 18.22 (2024): 14388-14402.

24. "Covid-19 Metabolomics and Diagnosis" (2023).

25. Rogal Julia., *et al*. "Stem-Cell Based Organ-On-a-Chip Models for Diabetes Research". *Advanced Drug Delivery Reviews* 140 (2019): 101-128.

26. Huang Wei., *et al*. "Revolutionizing Nephrology Research: Expanding Horizons with Kidney-On-a-Chip and Beyond". *Frontiers in Bioengineering and Biotechnology* 12 (2024).

27. Akarapipad Patarajarin., *et al*. "Environmental Toxicology Assays Using Organ-On-Chip". *Annual Review of Analytical Chemistry* (2021).

28. Kravchenko SV., *et al*. "Application of the Organ-On-a-Chip Technology in Experimental Ophthalmology". *Vestnik Oftal'mologii* 139.1 (2023): 114.

29. Bettadapur Archana., *et al*. "Prolonged Culture of Aligned Skeletal Myotubes on Micromolded Gelatin Hydrogels". *Scientific Reports* 6.1 (2016).

30. Barros Natan R., *et al*. "A Human Skin-On-a-Chip Platform for Microneedling-Driven Skin Cancer Treatment". *Materials Today Bio* 30 (2024): 101399.

31. Tsagkaris Aristeidis S., *et al*. "A Hybrid Lab-On-a-Chip Injector System for Autonomous Carbofuran Screening". *Sensors* 19.24 (2019): 5579.

32. Meneses J., *et al*. "Guiding Organs-On-Chips towards Applications: A Balancing Act between Integration of Advanced Technologies and Standardization". *Frontiers in Lab on a Chip Technologies* 3 (2024).

33. Piergiovanni Monica., *et al*. "Standardisation Needs for Organ on Chip Devices". *Lab on a Chip* 21.15 (2021): 2857-2868.

34. Teixeira Sonia Gomes., *et al*. "National Reflection on Organs-On-Chip for Drug Development: New Regulatory Challenges". *Toxicology Letters* 388 (2023): 1-12.

35. McCain Megan L., *et al*. "Recapitulating Maladaptive, Multiscale Remodeling of Failing Myocardium on a Chip". *Proceedings of the National Academy of Sciences* 110.24 (2013): 9770-9775.

36. Khalil Natalie N and Megan L McCain. "Engineering the Cellular Microenvironment of Post-Infarct Myocardium on a Chip". *Frontiers in Cardiovascular Medicine* 8 (2021).

37. Koyilot Mufeeda C., *et al*. "Breakthroughs and Applications of Organ-On-a-Chip Technology". *Cells* 11.11 (2022): 1828.

38. Maxey Antonina P., *et al*. "Regulation of Oxytocin-Induced Calcium Transients and Gene Expression in Engineered Myometrial Tissues by Tissue Architecture and Matrix Rigidity". *Current Research in Physiology* 6 (2023): 100108.

39. N Picollet-D'hahan., *et al*. "Encapsulated Organoids and Organ-On-a-Chip Platform for Cancer Modeling". 2021 IEEE International Electron Devices Meeting (IEDM 1) (2017): 10.6.1-10.6.4.

40. Ashammakhi Nureddin., *et al*. "Translating Advances in Organ-On-A-Chip Technology for Supporting Organs". *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 107.6 (2018): 2006-2018.

41. Alver Charles G., *et al*. "Roadblocks Confronting Widespread Dissemination and Deployment of Organs on Chips". *Nature Communications* 15.1 (2024).